This Company "Cleerly" Understands How to Diagnose Heart Disease

Dr. James Min, founder and CEO of Cleerly, joins us on this episode of Let’s Talk Medtech for a riveting discussion about cardiovascular disease during American Heart Month.

Omar Ford

February 11, 2022

1 Min Read
Image courtesy of Cleerly

It’s American Heart Month, and Cleerly, a startup that uses artificial intelligence to change the way we diagnose cardiovascular disease is keeping busy.

Dr. James, “Jim” Min, founder and CEO of Cleerly, joins us on this episode of Let's Talk Medtech for a discussion about American Heart Month and the company’s goals over the next few months.

Cleerly’s  technology was born out of research from the Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine and uses non-invasive coronary (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen algorithms capable of quantifying and characterizing the presence, extent, severity, and type of coronary artery disease and other cardiovascular disorders.

In June of 2021, the company raised $43 million in a series B financing. And just a few short days ago, Cleerly announced its latest product release, Cleerly 2.2.0, that includes user experience refinements and three new high-value tools. These updates allow Cleerly technology to enter into the clinical workflows of health systems and providers across the U.S., drive new efficiencies, and deliver new insights to customers. 

“At Cleerly, we are constantly improving our technology to better identify people with heart disease,” Min said. “Cleerly 2.2.0 includes a variety of advancements that will help physicians better evaluate and understand the plaque in patients’ hearts to prevent adverse cardiac events.” 



About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like